Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review

Bimekizumab is the most recent interleukin-17 inhibitor (IL-17i) to receive approval for adult plaque psoriasis; unlike other IL-17i agents, it exclusively targets IL-17A/IL-17F. While biologic switching is common in routine clinical practice, limited information exists on switching from another IL-17i agent to bimekizumab. We conducted a real-world, multicenter, retrospective study of bimekizumab use in the setting of prior IL-17i exposure.